Therefore, there is a great need to identify new therapies that target the underlying causes of AD, prevent or eliminate existing symptoms.2A dense accumulation of amyloid-β (Aβ), that is, a peptide resulting from amyloid precursor protein (APP) processing, and deposition of hyperphosphorylated tau protein appear in the CNS as AD pathology.3, 4AD is also closely associated with microvascular pathologies, such as degeneration and/or dysfunction in the microvascular structure, which are key places in the exchange of nutrients in the brain between the brain and circulating blood. This evidence concerns the gene APP and Alzheimer disease.